Issue 54, 2017, Issue in Progress

Anti-CD22-conjugated CdTe QDs co-loaded with doxorubicin and gambogic acid: a novel platform for lymphoma treatment

Abstract

Chemotherapy is the main treatment modality for lymphoma but may cause severe adverse effects. The number of patients who are refractory to conventional chemotherapeutic drugs continuously increases. We propose a novel drug delivery system comprising anti-CD22-conjugated cadmium–tellurium quantum dots (CdTe QDs) co-loaded with doxorubicin (DOX) and gambogic acid (GA; as a chemosensitizer). The system, designated as DOX/GA–CdTe–CD22, can be used for nanoparticle-based targeted combination chemotherapy. The system showed appropriate diameter, good dispersibility, high encapsulation efficiency, and high drug loading. The therapeutic and side effects were evaluated by in vitro and in vivo experiments. Results demonstrate that DOX/GA–CdTe–CD22 can precisely deliver drugs to tumor cells, thereby improving the antitumor activity of the drug and attenuating its toxicity against normal tissues. The enhanced efficacy could be due to increased apoptosis via the Bax/caspase-3/PARP pathway. This study suggests a novel and promising therapeutic option for lymphoma.

Graphical abstract: Anti-CD22-conjugated CdTe QDs co-loaded with doxorubicin and gambogic acid: a novel platform for lymphoma treatment

Supplementary files

Article information

Article type
Paper
Submitted
10 Apr 2017
Accepted
12 Jun 2017
First published
05 Jul 2017
This article is Open Access
Creative Commons BY-NC license

RSC Adv., 2017,7, 33905-33913

Anti-CD22-conjugated CdTe QDs co-loaded with doxorubicin and gambogic acid: a novel platform for lymphoma treatment

P. Xu, H. Zuo, D. Chen, M. Peng, Y. Jiang, X. Liu, J. Ouyang and B. Chen, RSC Adv., 2017, 7, 33905 DOI: 10.1039/C7RA04056C

This article is licensed under a Creative Commons Attribution-NonCommercial 3.0 Unported Licence. You can use material from this article in other publications, without requesting further permission from the RSC, provided that the correct acknowledgement is given and it is not used for commercial purposes.

To request permission to reproduce material from this article in a commercial publication, please go to the Copyright Clearance Center request page.

If you are an author contributing to an RSC publication, you do not need to request permission provided correct acknowledgement is given.

If you are the author of this article, you do not need to request permission to reproduce figures and diagrams provided correct acknowledgement is given. If you want to reproduce the whole article in a third-party commercial publication (excluding your thesis/dissertation for which permission is not required) please go to the Copyright Clearance Center request page.

Read more about how to correctly acknowledge RSC content.

Social activity

Spotlight

Advertisements